Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma

This publication has 14 references indexed in Scilit:

• Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma
  Cell Reports Medicine, 2025
• Mantle cell lymphoma: is it time for risk-adapted treatment?
  The Lancet Oncology, 2025
• Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials
  Leukemia, 2024
• Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy
  American Journal of Hematology, 2023
• Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
  HemaSphere, 2023
• Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
  Blood, 2020
• Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
  Blood, 2020
• Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi‐institutional study
  Genes, Chromosomes and Cancer, 2020
• Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients
  American Journal of Hematology, 2020
• The mutational footprints of cancer therapies
  Nature Genetics, 2019